Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma - Top-Institutions - MDSpire

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • By

  • Rakesh Popat

  • Bradley Augustson

  • Mercedes Gironella

  • Cindy Lee

  • Paul Cannell

  • Nashita Patel

  • Ravi S. Kasinathan

  • Rachel Rogers

  • Mehreen Shaikh

  • Amy Curry

  • Fernando Carreño

  • Sumita Roy-Ghanta

  • Joanna Opalinska

  • Hang Quach

  • October 21, 2024

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Cellular Therapy

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Clinical Trials

  • #4

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #5

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Oncology
    • Translational Research

Original Source(s)

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

  • by Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach

  • October 21, 2024

Related Content

Financial toxicity as logistical and relational burden across the lifespan during autologous transplant preparation

An ASCO preview: What to watch for at cancer research’s big meeting

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma